PackagingTop Companies
Packaging

Top Animal Vaccines Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Packaging

Published

Jan 2026

Share:

Packaging

Top Animal Vaccines Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
14.10 Billion
2026 Forecast (US$)
15.14 Billion
2032 Forecast (US$)
23.04 Billion
CAGR (2025-2032)
7.40%

Summary

The Animal Vaccines market is entering a sustained growth phase, underpinned by intensifying biosecurity standards, livestock productivity needs, and rising companion animal care. Leading Animal Vaccines market companies consolidate share through broad portfolios and global distribution. The sector is projected to grow from US$ 14.10 Billion in 2025 to US$ 23.04 Billion by 2032, at a 7.40% CAGR.

2025 Revenue of Top Animal Vaccines Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

Rankings of Animal Vaccines market companies are derived from a composite scoring framework integrating quantitative and qualitative metrics. Core inputs include estimated 2025 segment revenue, three-year growth trajectory, and share within key species segments (livestock, poultry, companion animals, aquaculture). We additionally assess pipeline depth, technology differentiation in platforms such as recombinant and vector vaccines, portfolio breadth across therapeutic areas, and geographic reach. Operational criteria cover manufacturing scale, fill-finish capabilities, quality and regulatory track record, and pharmacovigilance systems. Commercial factors examine distribution partnerships, channel access in emerging markets, and after-sales technical services. Strategic momentum is captured through M&A, licensing, R&D collaborations, and digital health integration. Each company receives normalized scores across dimensions; weightings emphasize revenue, innovation, and global coverage, yielding an overall rank that best reflects sustainable competitive advantage.

Top 10 Companies in Animal Vaccines

1
Zoetis Inc.
Companion animals, cattle, swine, poultry, aquaculture
Parsippany, New Jersey, USA
Recombinant vaccines, adjuvant optimization, diagnostics-linked vaccination programs
Approximately 24.00% of Animal Vaccines revenues
Undisputed scale leader among Animal Vaccines market companies with broadest portfolio and deep distribution footprint
Expanded biologics plant in Ireland, AI-enabled herd health platform partnerships, targeted acquisitions in poultry vaccines
US$ 3.40 Billion (estimate)
2
Boehringer Ingelheim Animal Health GmbH
Swine, ruminants, companion animals, poultry
Ingelheim, Germany
Vector vaccines, intranasal delivery, combination vaccines
Around 21.00%
Top-tier innovator with strong early-mover advantage in respiratory and reproductive disease vaccines
Incremental capacity additions in U.S. and China, co-development alliances in swine respiratory vaccines
US$ 2.90 Billion (estimate)
3
Elanco Animal Health Incorporated
Companion animals, poultry, cattle, aquaculture
Greenfield, Indiana, USA
Adjuvanted inactivated vaccines, combination products, precision dosing tools
Roughly 12.00%
Diversified player repositioning toward higher-margin biologics within Animal Vaccines market companies
Portfolio streamlining, divestment of non-core therapeutics, investments in biologics and digital engagement programs
US$ 1.65 Billion (estimate)
4
Ceva Santé Animale
Poultry, swine, ruminants, companion animals
Libourne, France
Vectored poultry vaccines, hatchery vaccination technologies, autogenous vaccines
Around 7.50%
Agile mid-sized leader with dominance in poultry and hatchery services globally
Hatchery automation rollouts in Latin America, strategic acquisitions in Asia, expanded autogenous portfolio
US$ 1.05 Billion (estimate)
5
Merck Animal Health (MSD Animal Health)
Cattle, swine, poultry, aquaculture, companion animals
Madison, New Jersey, USA
DNA-based vaccines, sensor-enabled monitoring, novel adjuvant systems
About 9.20%
Digitally enabled vaccine provider leveraging strong parent pharma capabilities
Integration of wearables with vaccine protocols, expansion of fish vaccine facilities in Norway and Chile
US$ 1.30 Billion (estimate)
6
Virbac SA
Companion animals, ruminants, aquaculture
Carros, France
Companion animal biologics, dermatology-linked vaccines, regional autogenous offerings
Approximately 5.70%
High-growth specialist positioned on premium companion animal and emerging market segments
Capacity additions in India and Brazil, increased R&D focus on companion animal vaccines
US$ 0.80 Billion (estimate)
7
Phibro Animal Health Corporation
Poultry, swine, cattle
Teaneck, New Jersey, USA
Inactivated and live poultry vaccines, autogenous solutions
Around 3.90%
Value-focused provider with strong integrator relationships in poultry vaccines
Strengthening contract manufacturing, partnerships with integrators in Latin America and Asia
US$ 0.55 Billion (estimate)
8
Hipra
Swine, poultry, ruminants, aquaculture
Amer, Spain
Next-generation adjuvants, thermostable formulations, herd-specific vaccines
Roughly 3.20%
Innovation-driven mid-cap with strong positioning in swine and poultry diseases
Investments in thermostable vaccine lines, increased direct presence in Southeast Asia and Africa
US$ 0.45 Billion (estimate)
9
Heska Corporation (now part of Mars/VCA ecosystem)
Companion animals
Loveland, Colorado, USA
Clinic-based biologics, diagnostics-vaccine integration, point-of-care platforms
About 1.80%
Niche companion animal specialist leveraging integrated veterinary clinic ecosystem
Synergy capture with Mars veterinary networks, expanded portfolio for canine and feline vaccines
US$ 0.25 Billion (estimate)
10
Vetoquinol SA
Companion animals, cattle, swine
Lure, France
Regional vaccine lines, combined therapeutic-preventive programs
Approximately 1.60%
Smaller but globally active player with strong veterinary relationships in Europe and North America
Portfolio rationalization, selective investments in viral vaccines for pets and cattle
US$ 0.22 Billion (estimate)

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Zoetis Inc.

Zoetis Inc. is the global leader in Animal Vaccines, offering a broad, innovation-led portfolio spanning livestock, poultry, and companion animals.

Key Financials: 2025 Animal Vaccines revenue US$ 3.40 Billion; R&D intensity approximately 8.50% of total sales.
Flagship Products: Core EQ Innovator, Vanguard canine vaccines, Poulvac poultry range
2025-2026 Actions: Expanded biologics manufacturing in Europe, deepened partnerships with integrated livestock producers, deployed digital herd-health platforms globally.
Three-line SWOT: Unmatched scale and portfolio depth; Exposure to livestock demand cycles; Opportunity—expand premium companion animal vaccines in emerging markets.
Notable Customers: Large integrated poultry producers, global dairy cooperatives, corporate veterinary hospital chains
2

Boehringer Ingelheim Animal Health GmbH

Boehringer Ingelheim Animal Health is a top-tier innovator, especially strong in swine and respiratory vaccines across major species.

Key Financials: 2025 Animal Vaccines revenue US$ 2.90 Billion; operating margin estimated around 20.00%.
Flagship Products: Ingelvac swine vaccines, Bovela cattle vaccines, companion animal respiratory vaccines
2025-2026 Actions: Increased capacity for swine vaccines, advanced vector-based platforms, expanded direct presence in China and Southeast Asia.
Three-line SWOT: Strong science-based culture and R&D engine; Portfolio complexity in some markets; Opportunity—capitalize on African swine fever vaccination programs.
Notable Customers: Global swine producers, veterinary distributors, mixed-animal veterinary practices
3

Elanco Animal Health Incorporated

Elanco Animal Health combines therapeutics and vaccines, with growing emphasis on biologics for companion animals and food-producing species.

Key Financials: 2025 Animal Vaccines revenue US$ 1.65 Billion; portfolio optimization driving mid-single-digit margin expansion.
Flagship Products: Galliprant adjunct vaccine programs, cattle respiratory vaccines, aquaculture vaccine lines
2025-2026 Actions: Rationalized non-core SKUs, redirected R&D to biologics, strengthened key account management across large veterinary chains.
Three-line SWOT: Diverse portfolio and strong brand; Integration and debt overhang from past M&A; Opportunity—expand biologics share and cross-sell to therapeutic customers.
Notable Customers: Corporate veterinary groups, poultry integrators, cattle feedlot operators
4

Ceva Santé Animale

Ceva Santé Animale is a fast-growing global specialist with leadership in poultry vaccines and hatchery vaccination technologies.

Key Financials: 2025 Animal Vaccines revenue US$ 1.05 Billion; high-single-digit constant-currency revenue growth.
Flagship Products: Vectormune poultry vaccines, Cevac hatchery range, swine reproductive vaccines
2025-2026 Actions: Expanded hatchery automation solutions, acquired regional poultry vaccine assets, reinforced autogenous production capabilities.
Three-line SWOT: Strong poultry franchise and service model; Less diversified than mega-players; Opportunity—penetrate emerging-market poultry consolidation wave.
Notable Customers: Global poultry integrators, regional hatcheries, specialized livestock veterinarians
5

Merck Animal Health (MSD Animal Health)

Merck Animal Health leverages advanced biologics and digital technologies to deliver integrated vaccination and monitoring solutions.

Key Financials: 2025 Animal Vaccines revenue US$ 1.30 Billion; double-digit growth in aquaculture and companion animal segments.
Flagship Products: Nobivac pet vaccines, Aquavac fish vaccines, Bovilis cattle vaccines
2025-2026 Actions: Linked sensor platforms with vaccination protocols, added capacity in Nordic aquaculture facilities, launched new companion animal vaccines.
Three-line SWOT: Access to cutting-edge research and capital; Complex integration of digital tools in field; Opportunity—scale sensor-vaccine ecosystems globally.
Notable Customers: Fish farming companies, cattle producers, companion animal clinics and hospitals
6

Virbac SA

Virbac SA is a diversified animal health company with strong positioning in companion animal vaccines and emerging markets.

Key Financials: 2025 Animal Vaccines revenue US$ 0.80 Billion; revenue CAGR around 7.00% over recent years.
Flagship Products: Companion animal core vaccines, ruminant clostridial vaccines, regional specialty vaccines
2025-2026 Actions: Invested in new vaccine plants in India and Brazil, enhanced companion animal vaccine pipeline, broadened distribution partnerships.
Three-line SWOT: Agility and focus on vets; Smaller scale versus top-tier rivals; Opportunity—capture fast growth in pet vaccines across emerging economies.
Notable Customers: Independent veterinarians, regional distributors, dairy and beef cooperatives
7

Phibro Animal Health Corporation

Phibro Animal Health focuses on value-driven vaccines and nutritional products for poultry, swine, and cattle producers.

Key Financials: 2025 Animal Vaccines revenue US$ 0.55 Billion; stable mid-teens EBITDA margins in vaccine business.
Flagship Products: Poultry inactivated vaccines, autogenous herd vaccines, respiratory disease vaccines
2025-2026 Actions: Scaled contract manufacturing, expanded alliances with large poultry integrators, reinforced Latin American commercial teams.
Three-line SWOT: Strong producer relationships and cost-competitive offerings; Limited companion animal footprint; Opportunity—expand custom autogenous solutions.
Notable Customers: Poultry integrators, swine producers, feed companies
8

Hipra

Hipra is an innovation-centric company specializing in swine, poultry, and ruminant vaccines with emphasis on advanced formulations.

Key Financials: 2025 Animal Vaccines revenue US$ 0.45 Billion; R&D spending near 10.00% of sales.
Flagship Products: Swine reproductive vaccines, thermostable poultry vaccines, bovine mastitis vaccines
2025-2026 Actions: Expanded thermostable vaccine lines, deepened presence in Asia and Africa, modernized European manufacturing assets.
Three-line SWOT: Strong formulation know-how and niche leadership; Smaller global salesforce; Opportunity—thermostable products for low-infrastructure markets.
Notable Customers: Regional livestock producers, integrators, veterinary cooperatives
9

Heska Corporation

Heska Corporation focuses on companion animal diagnostics and vaccines, integrated into a broader veterinary ecosystem.

Key Financials: 2025 Animal Vaccines revenue US$ 0.25 Billion; margin uplift from synergies within Mars veterinary networks.
Flagship Products: Clinic-focused canine and feline core vaccines, integrated diagnostic-vaccine plans
2025-2026 Actions: Leveraged Mars/VCA channels, expanded small-animal vaccine range, integrated cloud diagnostics data with preventive care plans.
Three-line SWOT: Strong captive channel access; Limited livestock capabilities; Opportunity—deepen preventive care bundles across Mars clinics.
Notable Customers: Companion animal veterinary clinics, corporate hospital networks, specialty pet clinics
10

Vetoquinol SA

Vetoquinol SA is a mid-sized European player offering a mix of therapeutics and vaccines for pets and production animals.

Key Financials: 2025 Animal Vaccines revenue US$ 0.22 Billion; steady low-single-digit organic growth.
Flagship Products: Pet core vaccines, bovine vaccines, swine respiratory vaccines
2025-2026 Actions: Rationalized legacy products, invested selectively in viral vaccine upgrades, strengthened direct vet engagement programs.
Three-line SWOT: Strong European vet relationships; Smaller scale limits R&D breadth; Opportunity—target under-served niches and regional alliances.
Notable Customers: European veterinary clinics, mixed-animal practices, regional distributors

SWOT Leaders

Zoetis Inc.

SWOT Snapshot

SWOT
Strengths

Largest global footprint, extensive species coverage, strong R&D pipeline, and deep relationships with veterinarians and integrators.

Weaknesses

High dependence on mature livestock markets exposes revenue to commodity cycles and regulatory shifts.

Opportunities

Premiumization of pet care, expansion in emerging markets, biologics innovation, and diagnostic-linked vaccination programs.

Threats

Intensifying competition from other Animal Vaccines market companies, biosimilar pressure, and evolving regulatory requirements.

Boehringer Ingelheim Animal Health GmbH

SWOT Snapshot

SWOT
Strengths

Robust innovation engine, strong respiratory and swine portfolios, and diversified geographic presence across key regions.

Weaknesses

Portfolio complexity, with overlapping brands in some markets, can dilute marketing focus and profitability.

Opportunities

Rising demand for swine and ruminant vaccines in Asia and Latin America, plus new vector technologies.

Threats

Disease pattern shifts, intermittent trade disruptions, and aggressive pricing by mid-tier Animal Vaccines market companies.

Elanco Animal Health Incorporated

SWOT Snapshot

SWOT
Strengths

Balanced mix of therapeutics and vaccines, improving focus on biologics, and strong corporate veterinary relationships.

Weaknesses

Legacy integration challenges and relatively higher leverage compared with some leading Animal Vaccines market companies.

Opportunities

Portfolio refocusing on high-growth vaccines, biologics-driven margin expansion, and cross-selling into existing customer base.

Threats

Competitive pressure from mega-players and regional specialists, plus potential reimbursement and pricing constraints.

Animal Vaccines Market Regional Competitive Landscape

North America remains the largest profit pool for Animal Vaccines market companies, supported by high companion animal spending, large commercial feedlots, and stringent disease control programs. Zoetis Inc., Merck Animal Health, and Elanco dominate, while mid-tier players compete on niche indications, autogenous vaccines, and bundled service models with corporate veterinary groups.

Europe is mature but innovation-intensive, driven by strict animal welfare regulations, traceability requirements, and strong veterinary infrastructures. Boehringer Ingelheim Animal Health, Ceva Santé Animale, Virbac, and Vetoquinol leverage deep local relationships. Growth focuses on differentiated biologics, reduced antibiotic use via vaccination, and improved cold-chain logistics, especially in Eastern and Southern European livestock clusters.

Asia Pacific is the fastest-growing region, propelled by expanding livestock herds, rising meat consumption, and improving biosecurity standards. Leading Animal Vaccines market companies such as Zoetis, Boehringer Ingelheim, Elanco, and Hipra invest heavily in local manufacturing, pricing adaptation, and distributor partnerships to capture swine, poultry, and aquaculture opportunities in China, India, Southeast Asia, and Oceania.

Latin America represents a strategic growth frontier, anchored by large poultry and beef export industries in Brazil, Mexico, and Argentina. Ceva’s poultry strength, alongside Zoetis, Merck Animal Health, and Phibro, creates intense competition. Market success hinges on integrator partnerships, field technical support, and robust surveillance-backed vaccination strategies across poultry, cattle, and swine operations.

The Middle East and Africa show rising demand as governments and producers address endemic diseases and food security. Animal Vaccines market companies expand via distributor-led models, pilot manufacturing, and government tenders. Hipra, Zoetis, and regional specialists increasingly tailor thermostable vaccines and training programs to overcome infrastructure gaps and variable cold-chain reliability.

Emerging Eastern European and Central Asian markets offer selective opportunities, particularly in poultry and dairy sectors undergoing modernization. Larger Animal Vaccines market companies partner with local distributors and cooperatives, focusing on cost-effective vaccines and farmer education. Success relies on navigating regulatory fragmentation and building disease monitoring systems with public-sector stakeholders.

Animal Vaccines Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

ImmuniTrace Biologics
Disruptor
USA

Developing mRNA-based animal vaccines with rapid strain-update capability, targeting high-mutation pathogens in poultry and swine supply chains.

BioStable VetTech
Disruptor
India

Focuses on thermostable vaccines for cattle and small ruminants, designed for minimal cold-chain dependency in rural and hot climates.

AquaGuard Vaccines
Disruptor
Norway

Specializes in novel injectable and immersion vaccines for salmon and warm-water aquaculture, integrated with farm-level data analytics.

VetNano Labs
Disruptor
Germany

Uses nanoparticle delivery platforms to enhance vaccine efficacy and reduce dosing volumes for companion animals and high-value livestock.

GenomicShield Animal Health
Disruptor
Brazil

Applies genomics and bioinformatics to design custom autogenous vaccines for large poultry and swine integrators across Latin America.

Clinix Preventive Platforms
Disruptor
United Kingdom

Cloud-native platform that links small-animal clinic data with personalized vaccination reminders and manufacturer portals for Animal Vaccines market companies.

Animal Vaccines Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Animal Vaccines market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Animal Vaccinesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.